Common misconceptions

Common mistake
Wrong: Uric acid is the primary nitrogenous waste product of amino acid catabolism excreted by the kidneys.
Right: Urea is the primary nitrogenous waste from amino acid catabolism, synthesized in the liver via the urea cycle; uric acid is the end product of purine catabolism.
Urea and uric acid are both nitrogenous wastes, but they come from completely different pathways. Urea is the end product of amino acid catabolism — the liver strips amino groups, converts them to ammonia, and runs the urea cycle to produce nontoxic urea that kidneys excrete. Uric acid, by contrast, is produced by xanthine oxidase from purine base degradation (adenine, guanine). Gout involves uric acid crystal deposition, not urea — keeping these metabolic origins distinct will save you from a classic MCAT distractor.
Common mistake
Wrong: Unconjugated bilirubin is water-soluble and can be directly excreted in bile.
Right: Unconjugated bilirubin is lipid-soluble and must be conjugated with glucuronate in the liver to become water-soluble for biliary excretion.
Students often assume that the form directly excreted must be the one already in circulation — but unconjugated bilirubin is actually lipid-soluble, which is why it travels bound to albumin in the blood and can't be filtered by the kidneys or secreted into bile. Hepatocytes conjugate bilirubin with glucuronate (via UDP-glucuronosyltransferase) to make it water-soluble, only then can it enter bile. This is why neonates with immature conjugating enzymes accumulate unconjugated bilirubin, which can cross the blood-brain barrier and cause kernicterus — a detail the MCAT loves.
Common mistake
Wrong: Phase II conjugation reactions always make drugs more toxic by adding charged groups that trap them in cells.
Right: Phase II conjugation (e.g., glucuronidation, sulfation) generally increases water solubility and facilitates renal or biliary excretion, reducing toxicity.
Phase II reactions are the liver's finishing move — their entire purpose is to neutralize reactive intermediates by attaching charged, water-soluble groups like glucuronate, sulfate, or glycine. This increases renal or biliary clearance and generally reduces biological activity. The confusion likely comes from Phase I, which can actually generate more reactive (more toxic) intermediates than the parent compound — that's the step that sometimes causes drug-induced liver injury. Phase II cleans up after Phase I. If Phase II conjugation were increasing toxicity, there would be no evolutionary logic to it.
Common mistake
Gap: Missing the concept of hepatic first-pass metabolism via the portal circulation reducing oral drug bioavailability
Orally absorbed drugs enter the hepatic portal circulation and are subject to first-pass metabolism by the liver before reaching systemic circulation, which can substantially reduce bioavailability.
When you swallow a drug, it's absorbed from the gut into the hepatic portal vein, which routes blood directly to the liver before it ever reaches systemic circulation. The liver metabolizes a fraction of the drug on this first pass, meaning less active drug makes it into the bloodstream — this is first-pass metabolism, and it explains why oral doses of many drugs must be much higher than IV doses to achieve the same plasma concentration. Drugs administered sublingually, rectally, or transdermally partially bypass this system, which is clinically relevant and fair game for the MCAT.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the full list of liver metabolic functions: gluconeogenesis, glycogen synthesis and breakdown, lipogenesis, synthesis of plasma proteins (albumin, clotting factors, fibrinogen), and urea synthesis from amino acid catabolism — the MCAT expects you to identify which of these fails in liver disease scenarios.
  2. Understand the two-phase drug detoxification system: Phase I uses cytochrome P450 enzymes to oxidize (or reduce/hydrolyze) compounds, often making reactive intermediates, and Phase II conjugates those intermediates with glucuronate, sulfate, or glutathione to make water-soluble products ready for excretion.
  3. Trace bilirubin from red blood cell breakdown through unconjugated (lipid-soluble, albumin-bound) to conjugated (water-soluble, excreted in bile) form — and predict what type of jaundice results from impaired conjugation versus impaired excretion versus hemolysis.
  4. Explain why orally administered drugs pass through the hepatic portal circulation before reaching systemic circulation, and why this first-pass metabolism reduces oral bioavailability compared to intravenous administration.

Can you avoid these mistakes?

A patient with severe cirrhosis presents with low plasma albumin, elevated ammonia, and a prolonged bleeding time. Which specific liver functions are failing, and what metabolic pathways underlie each abnormality?
An infant develops jaundice in the first week of life. Lab results show elevated unconjugated bilirubin with normal conjugated bilirubin levels. What enzyme is most likely deficient or immature, and why is unconjugated (but not conjugated) bilirubin dangerous to brain tissue?
A patient taking Drug X orally requires a dose three times higher than the IV dose to achieve therapeutic plasma levels. What anatomical and physiological mechanism explains this difference, and which route of blood flow is responsible?
Isoniazid (an antibiotic) undergoes Phase I oxidation to a reactive intermediate that can cause hepatotoxicity. If a patient's Phase II glucuronidation enzymes are highly induced, would you expect more or less hepatotoxicity compared to baseline, and why?

Related topics

See how your Anki deck covers this topic.

Upload your deck for a free audit →